The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have agreed on terms of reference for a cluster on orphan medicinal products, aiming to achieve a common understanding of each agency's regulatory approaches to orphan drug designation. The cluster, formalised on 23 February 2026, will serve as a confidential forum for discussing designation criteria, regulatory flexibility, incentives, legal challenges, paediatric considerations, and orphan similarity. The primary goal is to share experiences and decisions that have set precedents in how orphan designations are granted in the United States and Europe.
The cluster will hold teleconferences every three months, with ad-hoc meetings for pressing product-related assessments. Participants from EMA include staff from the Orphan Medicines unit and members of the Committee for Orphan Medicinal Products (COMP), while FDA will involve colleagues from the Office of Orphan Products Development (OOPD). The teleconferences will be co-chaired by both agencies, with chair responsibilities alternating. No observers from other regulatory authorities are foreseen.
Confidentiality is governed by existing bilateral information-sharing arrangements, and cluster members are prohibited from disclosing shared information without prior authorisation. The terms of reference also allow for in-depth discussions on specific topics to be moved to the broader Rare Disease Cluster (RDC) when appropriate.
The agreement impacts several stakeholders. For patients with rare diseases, the cluster could accelerate the development and availability of treatments by reducing regulatory duplication and fostering mutual understanding. Pharmaceutical companies developing orphan drugs may benefit from clearer, more consistent designation criteria across jurisdictions, potentially lowering compliance costs. However, the cluster's confidentiality provisions may limit transparency for patient advocates and civil society groups seeking insight into regulatory decision-making. For EMA and FDA staff, the cluster adds a recurring coordination workload but offers a structured mechanism to align practices and avoid conflicting precedents.
No immediate legislative or regulatory changes are expected; the cluster is a procedural coordination body. Its effectiveness will depend on the frequency and depth of exchanges, and whether discussions translate into harmonised guidance or designation outcomes.